ArticleRespiratory research2026
PLB1 enhances adhesion and invasion of Trichosporon asahii to lung epithelial cells: insights into the mechanisms of Cav1/JAK/STAT3-induced arginine metabolism.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTrichosporon asahii (T. asahii) is a lethal pathogen that infects immunocompromised individuals. This study aimed to investigate the PLB1-mediated invasion mechanism of T. asahii in lung epithelial cells.
methodsRecombinant PLB1 protein was purified and used to stimulate alveolar type II (AT-II) cells. Following, transcriptome sequencing was performed to identify downstream targets. Cells were infected with PLB1-overexpressing (PLB1OX) T. asahii and transfected with overexpression vectors for Cav1 (Cav1OE) and/or Arg2 (Arg2OE). Subsequently, the activation of JAK/STAT3 signaling, expression of arginine metabolic markers, inflammation levels, cell viability, membrane integrity, and co-localization of Cav1 with fungi were assessed. L-arginine and L-proline levels were quantified by high performance liquid chromatography. In vivo, immunosuppressed mice were injected with PLB1OX T. asahii and a Cav1OE vector. Lung pathology and internalized fungi were evaluated using hematoxylin–eosin and periodic acid-schiff staining, respectively. Arginine metabolism, inflammation, and fibrosis in lung tissues were assessed using the same methods.
resultsRecombinant PLB1 significantly inhibited AT-II cell viability. Infection with PLB1OX T. asahii promoted fungi internalization, disrupted membrane integrity, downregulated Cav1 expression, and activated both JAK/STAT3 signaling and arginine synthesis pathways in lung epithelial cells. The addition of a JAK2 agonist blocked the suppressive effects of Cav1 overexpression on JAK/STAT3 signaling and arginine metabolism in PLB1OX T. asahii-infected AT-II cells. Downstream, Arg2 was predicted as a potential target for Cav1 to exert its biological functions. Further in vitro experiments confirmed that Arg2 overexpression counteracted the increased antifungal capacity conferred by Cav1 overexpression. In mouse lung tissues, PLB1OX T. asahii infection downregulated Cav1, while enhancing JAK-STAT3 activation, arginine synthesis, inflammation, and fibrosis. These pathological and molecular changes were alleviated by Cav1 overexpression.
conclusionsPLB1OX T. asahii impaired antifungal defenses in lung epithelial cells through the Cav1/JAK/STAT3-mediated arginine metabolism, while triggering inflammation and fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.